Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Is adjuvant Gem-Cis better than capecitabine in operated node-positive extrahepatic cholangiocarcinoma? STAMP trial: Not a negative study.
- 101 patients
- 31.7% had R1 resection
- 2-year disease-free survival: 38.5% vs 25.1% (HR=0.96 (CI, 0.71–1.30), p=0.430)
- median overall survival: 35.7 mo (29.5–NE) vs 35.7 months (30.9–NE) [HR=1.08 (CI, 0.71–1.64), 1-sided p=0.404)
- Grade 3–4 AE: 84% vs 16%”
Read further.
Source: Erman Akkus/X